CLINICAL_TRIALS
trial_result
· 2022-10-14
Clinical Trial Update: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy [Phase 2]
Summary
Amgen completed a controlled Phase 2 trial of avacopan in C3 glomerulopathy. The study results were posted in October 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: C3 Glomerulopathy (C3G) | Phase 2 | Status: COMPLETED | Results posted: 2022-10-14